Floatz logo

Ribavirin

Myalgic Encephalomeyelitis/Chronic Fatigue Syndrome

Aarhus University HospitalSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Myalgic Encephalomeyelitis/Chronic Fatigue Syndrome cohort.

Asset / SponsorPhaseRating
.Gamma.-Hydroxybutyrate Sodium Salt
University of Medicine and Dentistry of New Jersey
Phase 4B
Noramitriptyline
Duke University
Phase 2B
Pyridostigmine
Brigham and Women's Hospital
Phase 2CCC
Naltrexone
Brigham and Women's Hospital
Phase 2CCC
Autologous Leukocytes, 89Zr-Oxine Labeled
University of Alabama at Birmingham
Phase 1CC
Citalopram
Vrije Universiteit Brussel
N/AD

Same molecule, other indications

Ribavirin is also rated in:

hepatitis C virus infectionActive
A
Indicative · Phase 4
82 / 100
View asset →
chronic hepatitis C virus infectionDormant
A
Indicative · Phase 4
82 / 100
View asset →
cirrhosis of liverActive
BBB
Indicative · Phase 4
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →